论文部分内容阅读
Challenges and Opportunities for Developing Radiosensitizers* Strong need for developing radiosensltizers Limited number of agents in the pipeline ready for radiation oncology clinical trials Limited preclinical data supporting clinical trials combining molecular therapeutics with radiation therapy Challenges in Industry and Academla Cancer drugs are first developed as a singk agcnt Limited industry expertisc in radiation biology and radiation oncology Limited access to various molecular targeted agents Unprecedented opportunities currently exist due to progress in cancer biology knowledge and mokcular targeted agent development